Long-term study on combinational therapy of SMP-508 with dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus

Trial Profile

Long-term study on combinational therapy of SMP-508 with dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Repaglinide (Primary) ; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 18 Nov 2014 Primary endpoint has been met (proportion of glycosylated haemoglobin (change in the HbA1c level compared with baseline)), according to a Sumitomo Dainippon Pharma media release.
    • 19 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top